Selvester score predicts implantable cardioverter defibrillator shocks in patients with non-ischemic cardiomyopathy

被引:1
作者
Arisoy, Fazil [1 ]
Ozcan Celebi, Ozlem [2 ]
Erbay, Ilke [2 ]
Tufekcioglu, Omac [2 ]
Aydogdu, Sinan [2 ]
Temizhan, Ahmet [2 ]
机构
[1] Kilis State Hosp, Dept Cardiol, Kilis, Turkey
[2] Univ Hlth Sci, Ankara City Hosp, Dept Cardiol, Ankara, Turkey
关键词
ICD; non ischemic cardiomyopathy; Selvester score; shock; SUDDEN CARDIAC DEATH; QRS SCORE; PRIMARY PREVENTION; THERAPY; MANAGEMENT; AMIODARONE;
D O I
10.1002/joa3.12571
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The implantable cardiac defibrillator is the cornerstone of prevention of sudden cardiac death in non-ischemic cardiomyopathy. The Selvester score, which is frequently investigated in ischemic cardiomyopathy, has not been investigated in the field of non-ischemic cardiomyopathy. Aim: The aim of this study was to evaluate the Selvester score for determining appropriate implantable cardiac defibrillator shocks in non-ischemic cardiomyopathy patients. Materials and methods: In all, 131 non-ischemic cardiomyopathy patients were included in the study. A simplified Selvester score was calculated from ECG data. Patients were divided into two groups according to whether they received ICD shock. Results: Of the patients, 28.2% received appropriate implantable cardiac defibrillator shock. The Selvester score was significantly higher in patients receiving appropriate shock when compared to patients with no implantable cardiac defibrillator shocks (8.8 +/- 4.6 vs 7.2 +/- 3.3, P = .040). The median QRS duration was significantly longer in patients receiving appropriate shock than in patients with no shocks (130.14 +/- 35.08 ms vs 120.12 +/- 20.57 ms, P = .045). We determined that the cutoff value for the Selvester score to predict ICD shocks was 6.5 with a sensitivity of 72.0% and a specificity of 83% (AUC = 0.717; %95 GA: 0.627-0.807, P < .001). Conclusion: Selvester score was higher in patients receiving appropriate shock than in patients who did not receive any implantable cardiac defibrillator shock. From this study, the Selvester score is associated with the risk of ventricular tachycardia/ventricular fibrillation in non-ischemic cardiomyopathy so that careful attention is necessary to manage the patients with high Selvester score.
引用
收藏
页码:1046 / 1051
页数:6
相关论文
共 50 条
  • [31] Incidence of appropriate cardioverter-defibrillator shocks and mortality in patients with implantable cardioverter-defibrillators with ischemic cardiomyopathy versus nonischemic cardiomyopathy at 33-month follow-up
    Gandhi, Kaushang
    Aronow, Wilbert S.
    Desai, Harit
    Amin, Harshad
    Lai, Hoang M.
    Frishman, William H.
    Cohen, Martin
    Sorbera, Carmen
    ARCHIVES OF MEDICAL SCIENCE, 2010, 6 (06) : 900 - 903
  • [32] Cardioverter–defibrillator does not improve short-term survival among patients with non-ischemic cardiomyopathy and reduced left ventricular ejection fraction
    Clemens Jilek
    Thorsten Lewalter
    Matthias Pauschinger
    Wolfgang von Scheidt
    Lutz Frankenstein
    Otmar Pfister
    Rainer Hambrecht
    Oliver Bruder
    Johannes Brachmann
    Andreas Hartmann
    Ruth Strasser
    Matthias Hochadel
    Jochen Senges
    Clinical Research in Cardiology, 2020, 109 : 115 - 123
  • [33] Cardiac Magnetic Resonance as Risk Stratification Tool in Non-Ischemic Dilated Cardiomyopathy Referred for Implantable Cardioverter Defibrillator Therapy-State of Art and Perspectives
    Argentiero, Adriana
    Carella, Maria Cristina
    Mandunzio, Donato
    Greco, Giulia
    Mushtaq, Saima
    Baggiano, Andrea
    Fazzari, Fabio
    Fusini, Laura
    Muscogiuri, Giuseppe
    Basile, Paolo
    Siena, Paola
    Soldato, Nicolo
    Napoli, Gianluigi
    Santobuono, Vincenzo Ezio
    Forleo, Cinzia
    Garrido, Eduard Claver
    Di Marco, Andrea
    Pontone, Gianluca
    Guaricci, Andrea Igoren
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (24)
  • [34] Cardioverter-defibrillator does not improve short-term survival among patients with non-ischemic cardiomyopathy and reduced left ventricular ejection fraction
    Jilek, Clemens
    Lewalter, Thorsten
    Pauschinger, Matthias
    von Scheidt, Wolfgang
    Frankenstein, Lutz
    Pfister, Otmar
    Hambrecht, Rainer
    Bruder, Oliver
    Brachmann, Johannes
    Hartmann, Andreas
    Strasser, Ruth
    Hochadel, Matthias
    Senges, Jochen
    CLINICAL RESEARCH IN CARDIOLOGY, 2020, 109 (01) : 115 - 123
  • [35] Incidence and predictors of appropriate therapies delivered by the implantable cardioverter defibrillator in patients with ischemic cardiomyopathy: A systematic review
    Gracieux, Juneve
    Sanders, Gillian D.
    Pokorney, Sean D.
    Lopes, Renato D.
    Thomas, Kevin
    Al-Khatib, Sana M.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2014, 177 (03) : 990 - 994
  • [36] Predictors of Appropriate Implantable Cardioverter Defibrillator (ICD) Therapy in Primary Prevention Patients with Ischemic and Nonischemic Cardiomyopathy
    Verma, Atul
    Sarak, Bradley
    Kaplan, Alexander J.
    Oosthuizen, Richard
    Beardsall, Marianne
    Wulffhart, Zaev
    Higenbottam, Janet
    Khaykin, Yaariv
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2010, 33 (03): : 320 - 329
  • [37] Current Indications for Implantable Cardioverter Defibrillators in Non-Ischemic Cardiomyopathies and Channelopathies
    Gonzalez-Torrecilla, Esteban
    Arenal, Angel
    Atienza, Felipe
    Datino, Tomas
    Bravo, Loreto
    Ruiz, Pablo
    Avila, Pablo
    Fernandez-Aviles, Francisco
    REVIEWS ON RECENT CLINICAL TRIALS, 2015, 10 (02) : 111 - 127
  • [38] Determinants of inappropriate implantable cardioverter-defibrillator shocks: the German Device Registry perspective
    Safak, Erdal
    Eckardt, Lars
    Jung, Werner
    Ince, Hueseyin
    Senges, Jochen
    Hochadel, Matthias
    Perings, Christian
    Spitzer, Stefan
    Brachmann, Johannes
    Seidl, Karlheinz
    Hink, Hans Ulrich
    D'Ancona, Giuseppe
    JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY, 2019, 56 (01) : 71 - 77
  • [39] Primary prevention implantable cardioverter-defibrillator use in non-ischemic dilated cardiomyopathy based on arrhythmic risk stratification and left ventricular reverse remodeling prediction
    Muhammed, Ahmed
    Abdelazeem, Mohamed
    Elewa, Mohamed Gamaleldin
    Sharief, Mohamed
    Ammar, Ahmed
    HEART FAILURE REVIEWS, 2023, 28 (01) : 229 - 240
  • [40] Antitachycardia pacing for reduction of implantable cardioverter-defibrillator shocks
    Cantillon, Daniel J.
    Wilkoff, Bruce L.
    HEART RHYTHM, 2015, 12 (06) : 1370 - 1375